Poor
Mostly Misaligned
Patient Risk:
High
Summary
Many claims cannot be verified because key label text (Indications, Dosage/Administration, Warnings/Precautions, Adverse Reactions, etc.) is not present in the provided excerpts. Several pharmacokinetic/formulation/dosing claims appear mismatched or contradicted by the supplied label snippets (e.g., Vd units/qualifiers; oral liquid availability). Safety-critical label adherence cannot be assessed, creating high audit risk.
Category Scores
Accurate Statements
Losartan is an angiotensin II receptor antagonist (ARB.
11 DESCRIPTION: “Losartan potassium, USP is an angiotensin II receptor blocker acting on the AT1 receptor subtype.”
Losartan works by blocking the action of angiotensin II at the AT1 receptor.
12.1 Mechanism of Action: “Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking… the AT1 receptor…”
Losartan is available as tablets for oral administration (25 mg, 50 mg, 100 mg).
11 DESCRIPTION and 3 DOSAGE FORMS AND STRENGTHS: Tablets for oral administration and listed strengths.
Losartan dose exposure is only minorly affected by meals (food slows absorption and decreases Cmax; AUC effects are minor).
12.3 Pharmacokinetics: “A meal slows absorption of losartan and decreases its Cmax but has only minor effects on losartan AUC…”
Unsupported Statements
Losartan is prescribed to treat high blood pressure.
Supplied label excerpts for 1 INDICATIONS AND USAGE contain only the section heading; no indication text is provided to verify this claim.
Losartan is prescribed to protect the kidneys from damage.
No kidney-protection indication text is provided in the supplied label excerpts (1 INDICATIONS AND USAGE only shows a heading).
The volume of distribution (Vd) of losartan is influenced by the patient's body weight.
12.3 Pharmacokinetics provided distribution/clearance values, but does not state that body weight influences Vd.
Body weight is a significant predictor of losartan clearance.
12.3 Pharmacokinetics excerpt provided does not state that body weight predicts clearance.
Patients with a higher body weight require a higher dosage of losartan to achieve the same therapeutic effect.
No weight-threshold dose-response statements are provided in the supplied 2 DOSAGE AND ADMINISTRATION excerpts.
The volume of distribution of losartan increases with body weight.
No statement relating Vd to body weight is provided in the supplied excerpts.
According to FDA, the recommended dosage of losartan for adults is 50 mg once daily.
No adult dosing recommendation statements are present in the supplied 2 DOSAGE AND ADMINISTRATION excerpts.
The recommended dosage of losartan for adults can be adjusted based on the patient's body weight.
No body-weight-based adult dose adjustment instructions are provided in the supplied 2 DOSAGE AND ADMINISTRATION excerpts.
Patients with a body weight of 50 kg or less should receive a starting dose of 25 mg once daily of losartan.
No weight-threshold dosing instructions are provided in the supplied 2 DOSAGE AND ADMINISTRATION excerpts.
Patients with a body weight of 50-80 kg should receive a starting dose of 50 mg once daily of losartan.
No weight-threshold dosing instructions are provided in the supplied 2 DOSAGE AND ADMINISTRATION excerpts.
Patients with a body weight of more than 80 kg may require a higher dosage of 100 mg once daily of losartan.
No weight-threshold dosing instructions are provided in the supplied 2 DOSAGE AND ADMINISTRATION excerpts.
It is recommended to take losartan with food to minimize gastrointestinal side effects.
12.3 Pharmacokinetics provides a meal effect on absorption/Cmax/AUC but does not provide a recommendation to take with food to minimize GI side effects in the supplied excerpts.
Common side effects of losartan include dizziness.
6 ADVERSE REACTIONS excerpt contains only the section heading; no adverse reaction list is provided to verify dizziness.
Common side effects of losartan include headache.
6 ADVERSE REACTIONS excerpt contains only the section heading; no adverse reaction list is provided to verify headache.
Common side effects of losartan include fatigue.
6 ADVERSE REACTIONS excerpt contains only the section heading; no adverse reaction list is provided to verify fatigue.
Contradictions
Low
AI Statement
Losartan is available in tablets and oral liquid.
Label Reference
11 DESCRIPTION and 3 DOSAGE FORMS AND STRENGTHS (provided excerpts)
Low
AI Statement
The Vd of losartan is approximately 34 liters per kilogram (L/kg) in healthy individuals.
Label Reference
12.3 Pharmacokinetics Distribution: “volume of distribution… is about 34 liters” (no “per kilogram” unit and no “healthy individuals” qualifier provided in excerpt)
Important Omissions
No evaluation of boxed warnings, contraindications, pregnancy/fetal risk warnings, lactation, or other safety-critical label content (e.g., monitoring/renal considerations) is possible from the provided label excerpts.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Multiple dosing and adverse-effect claims are not verifiable from provided excerpts, and key safety-critical label sections (contraindications/boxed warnings/warnings/precautions/adverse reaction listings) are not available for assessment. This materially limits label adherence confidence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Misaligned
Primary Issue
Weight-threshold dosing and adult recommended dosing are asserted without any supporting 2 DOSAGE AND ADMINISTRATION label text in the provided excerpts; adverse reaction “common” claims are not supported because the adverse reaction list is not included; additional formatting/unit mismatch exists for Vd and an unsupported oral liquid product is claimed.
Suggested Improvement
Re-audit using the full text for 1 INDICATIONS AND USAGE, 2 DOSAGE AND ADMINISTRATION (including any weight-based dosing language), 4 CONTRAINDICATIONS, 5 WARNINGS AND PRECAUTIONS, 6 ADVERSE REACTIONS (actual listed reactions), and any listed dosage forms (confirm whether any oral liquid/suspension is actually described).